Live Breaking News & Updates on Chinook therapeutics inc
Stay updated with breaking news from Chinook therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novartis Pharma AG: Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Investigation announced for Investors who lost money with openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.
Lawsuit filed for Investors who lost money with shares openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.
Visiongain has published a new report entitled Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033: Forecasts by Therapeutic Application...
Novartis Weighs Selling Assets from Radiopharma Unit bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company's strategy and the broader industry trend to shed low-growth segments.
Versor Investments LP bought a new stake in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 348,543 shares of the company’s stock, valued at approximately $13,391,000. Chinook Therapeutics accounts for about 2.3% of Versor […]
EcoR1 Capital LLC lowered its position in Chinook Therapeutics, Inc. (NASDAQ:KDNY – Free Report) by 35.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 445,550 shares of the company’s stock after selling 244,450 shares during the quarter. EcoR1 Capital LLC’s holdings […]
EcoR1 Capital LLC reduced its stake in Chinook Therapeutics, Inc. (NASDAQ:KDNY – Free Report) by 35.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 445,550 shares of the company’s stock after selling 244,450 shares during the period. EcoR1 […]
Suvretta Capital Management LLC increased its stake in Chinook Therapeutics, Inc. (NASDAQ:KDNY – Free Report) by 8.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,568,797 shares of the company’s stock after purchasing an additional 123,967 shares during the quarter. Chinook Therapeutics […]